BIOINTERFACE RESEARCH IN APPLIED CHEMISTRY

ORIGINAL ARTICLE

www.BiointerfaceResearch.com

ISSN 2069-5837

Volume 1, Issue 3, 2011, 111-118

Received: 10.05.2011 / Accepted: 05.06.2011 / Published on-line: 15.06.2011

Phenotypical studies of raw and nanosystem embedded *Eugenia carryophyllata* buds essential oil antibacterial activity on *Pseudomonas aeruginosa* and

Staphylococcus aureus strains

Crina Saviuc ^{1,2}*, Alexandru Mihai Grumezescu³, Alina Holban¹, Coralia Bleotu⁴, Carmen Chifiriuc¹, Paul Balaure², Veronica Lazar¹

ABSTRACT

Considering the large number of the multiresistant bacterial strains and the increasing need in new antimicrobial formulation, the aim of this study was to evaluate the antipathogenic effect of *E. caryophyllata* essential oil on collection and recently isolated clinical strains of *P. aeruginosa* and *S. aureus*. Experimental assays were carried out by *in vitro* and *in vivo* tests. Qualitative and quantitative assessment of the antimicrobial activity was followed by the analysis of the essential oil influence on enzymatic soluble virulence factors expression. The cytotoxic effect of the vegetal extract was quantified by using HeLa cells. Nanosystem embedded essential oil was used to establish the *in vivo* antipathogenic effect on mice. Qualitative screening results revealed an early microbicidal effect quantified by low minimum inhibitory concentration values. The *in vivo* study showed a stabiliziation of the essential oil biological activities when using nanosystem embedding, that could be used for the design of proper formulations for delivery systems with antimicrobial effect.

Keywords: Eugenia carryophyllata, strains pathogenesis, nanosystem, coated nanoparticles

1. Introduction

Staphylococcus aureus and Pseudomonas aeruginosa are the most important opportunistic bacterial pathogens in hospitalized patients and immunocompromised hosts. S. aureus is a major human pathogen which can cause serious, severe infections such as endocarditis, septicemia, pneumonia and toxic shock syndrome [1]. Due to the continuous emergence and spread of antibiotic resistant strains (e.g. MRSA, VRSA) the treatment options are often severely limited [2,3]. P. aeruginosa is an important cause of nosocomial pneumonia, as well as a major pulmonary pathogen in patients with cystic fibrosis and other immunocompromising conditions [4, 5]. Persistent bacterial

¹ Microbiology Department, Faculty of Biology, University of Bucharest, Romania

² S.C. Biotehnos S.A., Romania

³ Organic Chemistry Department, Faculty of Applied Chemistry and Materials Science, Politehnica University of Bucharest, Romania

^{*}Corresponding author e-mail address: crina.saviuc@yahoo.com

⁴ S. Nicolau Institute of Virology, Bucharest, Romania

infections involving the opportunistic pathogen *P. aeruginosa* are responsible for much of the morbidity and mortality caused by cystic fibrosis.

The pathogenesis of *P. aeruginosa* and *S. aureus* infections is multifactorial, as suggested by the large number of cell-associated and extracellular virulence determinants possessed by the bacterium. Some of these determinants help colonization, whereas others facilitate bacterial invasion.

Because antibiotic resistances are spreading, current treatment strategies of *S. aureus* infections are becoming more and more ineffective finding a new antimicrobial strategies being of great interest.

Known for their antiseptic, i.e. bactericidal, virucidal and fungicidal, and medicinal properties essential oils are used in embalment, foods preservation and as antimicrobial agents. Essential oils contain a large number of compounds in a complex mixture with multitarget effects on bacterial cells, but many of the compounds are chemically unstable and easily volatile. A large variety of methods can be applied to lower the volatility of essential oils compounds in order to use them for the design of a final product, or for the improvement of the laboratory assay of the biological effects of these compounds [5, 6].

The aim of this study was to evaluate the antipathogenic effect of *E. caryophyllata* essential oil using a stabilizing nanosystem based method.

2. Experimental section

2.1. Plant material and extraction. *E. carryophyllata* dried buds were purchased from a local supplier and subjected for the essential oil extraction. A Neo Clevenger type apparatus according to European Pharmacopoeia 6 was used performing two microwave assisted extractions from 225g plant material.

2.2. Essential oil GC-MS analysis. Chemical composition was settled by GC-MS analysis. Gas chromatographic analysis was performed using an Agilent 6890 Series GS System gas chromatograph Detection was carried out with a 5973 mass-selective single quadrupole detector (Agilent technologies). Operation control and the data process were carried out by Agilent Technologies ChemStation software (Santa Clara, CA, USA). The mass spectrometer was calibrated before use with perfluorotributylamine (PFTBA) as a calibration standard. GC-MS parameters was described in a previous study. [7].

2.3. Bacterial strains. The antimicrobial activity of the *E. carryophyllata* buds essential oil was tested against bacterial strains recently isolated from clinical specimens as well as reference strains belonging to *S. aureus* and *P. aeruginosa* species (Table 1). The strains were identified by using an automatik Vitec II system. Bacterial suspensions from 15-18 h bacterial cultures developed on solid media were adjusted to 0.5 McFarland density and used for bioassays. The antimicrobial activity was tested on Brain Heart Infusion agar and Chapman media recommended for the tested strains.

2.4. In vitro tests for the antipathogenic effect of the essential oil

2.4.1. Qualitative screening of the antimicrobial effect. A killing time curve was performed for the tested strains. A stock solution essential oil (EO):dimethyl sulfoxide (DMSO) 1:1 was prepared and added to BHI broth, a concentration of 0.250μ L/mL EO being achieved. The qualitative screening of the antimicrobial effect and its dynamic was assessed after 1', 3', 5', 15' and 30' of contact, by performing viable cell counts.

Phenotipical studies for raw and nanosystem embedded *Eugenia carryophyllata* buds essential oil effect on *Pseudomonas aeruginosa* and *Staphylococcus aureus* strains

2.4.2. Quantitative assay of the antimicrobial activity. MIC (Minimal Inhibitory Concentration) value for the EO was determined by twofold microdilution technique, in 96 multi-well plates, starting from 250μ L/mL to 0.125μ L/mL, for each tested bacterial strain. Simultaneously, there were achieved serial dilutions for DMSO in the same volume, in order to obtain the negative control. An amount of 20 μ L of bacterial suspension with the standard density of 0.5 Mc Farland was added in each well. The plates were incubated for 24 h at 37°C, and MICs were read as the lowest EO concentration that inhibited the microbial growth.

Taber 1. Chinear ongin and species assignment of the strains								
Strains	Code	Clinical specimen	ecimen Strains		Clinical specimen			
S. aureus	1	Sputum	P. aeruginoasa	12	Sputum			
S. aureus	2	Sputum	P. aeruginoasa 13		Bronchotracheal			
S. aureus	3	Would secretion	P. aeruginoasa	14	Blood cultures			
S. aureus	4	Would secretion	P. aeruginoasa	15	Urine cultures			
S. aureus	5	Would secretion	P. aeruginoasa	16	Sputum			
S. aureus	6	Would secretion	P. aeruginoasa	17	Sputum			
S. aureus	7	Would secretion	P. aeruginoasa	18	Sputum			
S. aureus	8	Would secretion	S. aureus	19	Blood cultures			
P. aeruginoasa	9	Blood cultures	S. aureus	20	Blood cultures			
P. aeruginoasa	10	Blood cultures	S. aureus	II	ATCC 25923			
P. aeruginoasa	11	Blood cultures						

Tabel 1: Clinical origin and species assignment of the strains

2.4.3. Influence of the EO on the expression of soluble enzymatic virulence factors. The microbial strains were cultivated in nutrient broth with and without addition of subinhibitory concentrations of EO for each strain and the obtained overnight bacterial cultures were used for the performance of the following virulence tests: Plate haemolysis, Protease activity, DNA-se production, Lipase production, Amylase production, Esculin hydrolysis described in a previous study, using methods previously described [8].

2.5. Nanosystem embedded *Eugenia carryophyllata* buds essential oil. Magnetite nanoparticles was synthesized by Massart method [9]. Core/shell nanosystem was prepared under microwave condition. Oleic acid was used as surfactant to create the shell. The hybrid nanostructure was prepared according to scheme 1.



[1] solubilization of core/shell nanosystem in chloroform; [2] essential oil added drop by drop; [3,5] mixing until evaporation the chloroform; [4] chloroform added drop by drop. Scheme 1: Core/shell/extra-shell hybrid nanostructure

2.6. In vitro cytotoxic effect of the essential oil. 5×10^5 HeLa cells were seeded in 25 cm² flask, in Dulbecco's Modified Essential medium DMEM (Sigma) supplemented with 10% fetal calf serum (Sigma) at 37°C, 5% CO₂, in a humid atmosphere. These cells were treated with different dilutions of essential oil stock solution as follows: 1/1000; 1/5000; 1/10000; 1/50000. After 24 h of treatment, cells viability was evaluated using Trypan Blue stain, and the cells were processed for cell cycle analysis. Briefly, the cells were washed in a cold solution of PBS (pH 7.5), then fixed in cold 70% ethanol and stored at -20 ^oC overnight. The samples were then centrifuged, washed with PBS and then re-suspended in 100 µl PBS, treated with 10 µl 0.1% RNase A and labelled with 10 µl propidium iodide (10 µg/ml), incubated in the dark at RT for 30 min prior measurement. DNA content of cells was quantified by a FACSCALIBUR flow cytometer and analyzed using FlowJo 8.8.6. software (Ashland, Oregon, USA).

2.7. In vivo evaluation of the antipathogenic effect of the essential oil

2.7.1. Mice. Generally, mice were 4-5 weeks females or males weighing about 25g. Mice were housed in filtered, clear plastic cages on a 12-h light/dark cycle. Food and water were provided *ad libitum*.

2.7.2. In vivo tests protocol. Feeding suspensions were prepared from stock suspensions EO:DMSO 1:1, stabilized EO:DMSO. A 4mL volume of working suspentions was achieved, at 30μ L/mL concentration of the EO. Mice were pretreated for 1 week by oral administration (100 μ L) with different working suspentions: EO, stabilized EO, ferite nanoparticles, 4 animals/variant. After 1 week half of the mice were injected retroperitoneally with 200 μ L of a bacterial suspension of 0.5 McFarland density obtained from 16-18h solid culture of *P. aeruginosa* 11. The oral treatment based on EO was carried out for another 2 weeks, following the infection. The mice were evaluated by daily inspection of their behaviour, weight and aspect of the injection site.

3. Results section

3.1. Essential oil GC-MS analysis. The average yields of essential oil (v/w %, normalized to the part of the plant mass dried weight) extracted from *E. caryophyllata* was 2.25%. The EO from dried buds of *E. caryophyllata* proved to be reach in eugenol and α -cariophylene (92.42% and 5.44% from the total aria) [10]. The qualitative screening for the EO antimicrobial activity proved an early microbicidal effect exhibited on all tested strains (Figure 1). As it could be noticed from Figure 2, the MIC values were generally low especially for *S. aureus* strains (code 1 to 8 and 19 to 21) ($\leq 1\mu$ L/mL).

3.2. Influence of the EO on the expression of soluble enzymatic virulence factors. The soluble enzymatic virulence factors expression was stimulated by the EO subinhibitory concentrations, particularly in case of lipase production (15 strains, both *S. aureus* and *P. aeruginosa*) followed by DN-ase, haemolysins, gelatinase and lecithinase, in case of *P. aeruginosa* strains) (Table 6).



Figure 2: The graphic representation of the MIC values obtained for the EO on different bacterial strains

Phenotipical studies for raw and nanosystem embedded Eugenia carryophyllata buds essential oil effect on Pseudomonas aeruginosa and Staphylococcus aureus strains



Figure 1: Assessment of the antimicrobial activity of the essential oil by viable cell counts

Table 6. Influence of the EO on the expression of soluble enzymatic virulence factors												
Virulence factors Bacterial Strains	nce tors DNA-se		Lecitinase		Lipase		Gelatinase		Esculin hydrolysis		Hemolysins	
	C*	EO**	С	EO	С	EO	С	EO	С	EO	С	EO
1	-	-	-	-	-	+	-	-	-	-	-	-
2	-	-	-	-	-	+	-	-	-	-	-	-
3	-	-	-	-	-	+	-	-	-	-	-	-
4	-	-	-	-	-	+	-	-	-	-	-	-
5	-	-	-	-	-	+	-	-	-	-	-	-
6	-	-	-	-	-	+	-	-	-	-	-	-
7	-	-	-	-	-	+	-	-	-	-	-	-
8	-	-	-	-	-	+	-	-	-	-	-	-
9	-	-	-	-	+	+	+	+	-	-	-	-
10	-	+	-	+	+	+	+	+	-	-	-	α+
11	-	+	-	+	+	+	-	-	-	-	-	-
12	-	-	-	-	-	+	-	-	-	-	α+	α+
13	+/-	+	-	-	-	+/-	+	+	+	+	β+	β++
14	+/-	+	-	-	-	+/-	-	+/-	-	-	-	-
15	-	-	-	-	+	+	+	+/-	+/-	+/-	α+	α/ β+
16	+	+	-	-	-	+	-	-	-	-	β+	β+
17	-	-	-	-	-	+	-	-	-	-	-	β++
18	-	-	-	-	-	+	-	-	-	-	-	α+
19	-	+	+	+	+	+	-	-	+	-	β+	β+
20	-	+	-	-	-	+	-	-	+	+/-	-	β+
II	-	-	-	-	+	+	-	-	+	+/-	β+	β +

11 (T CI	C(1 E	0 1		C 1 1 1	· ·	• 1 • • •	
able 6.	Influence	of the E	O on the	expression	of soluble (enzymatic	virulence factors	

*Control, **Essential oils

3.3. Nanosystem embedded *Eugenia carryophyllata* **buds EO.** HR-TEM was used as primary method for the characterization of core/shell nanosystem [9]. The dimension of nanoparticles did not exceed 20 nm.



Figure 3. Magnetic field aligns the core/shell/extra-shell nanofluid

3.4. In vitro cytotoxic effect of the essential oil. The cell cycle analysis was conducted with the Watson (pragmatic) model (Table 7, Figure 4). Decrease in G0/G1 and increase in synthesis phase was noted in the presence of the essential oil. The cell cycle analysis of HeLa cells treated with increased concentrations of the essential oil (1:5000 dilution) revealed in the left side the appearance of subG0 apoptosis peak, that confirmed the results of Tripan Blue evaluation



Figure 4: Viability evaluation of HeLa cells treated with different essential oil concentration

		00/01	5	02/101	
	Control	70.46	23.96	7.96	
	Oil dilution 1:50.000	67.86	24.41	5.85	
	Oil dilution 1:10.000	56.04	33.99	5	
	Oil dilution 1:5.000	49.88	33.87	7.68	
0 Events 1024	1023 0 FL3	FL3	23	700 0 0 FL3	1023

Table 7: The effects of essential oil on HeLa cell cycle progression $GO/G1 = \frac{1}{S} = \frac{G2}{M}$



Phenotipical studies for raw and nanosystem embedded *Eugenia carryophyllata* buds essential oil effect on *Pseudomonas aeruginosa* and *Staphylococcus aureus* strains

3.5. In vivo evaluation of the antipathogenic effect of the essential oil. After two days of *P. aeruginosa* inoculation by intraperitoneal route, a localized infection appeared in all animals at the injection site, except for the group pretreated with nanosystem embedded stabilized EO (Figure 6). No mortality rate was registered on the entire duration of the experiment.





Figure 6: The effect on *P. aeruginosa* 11 pathogenesis on mice **a.** the occurrence of a localized infection at the injection ste in all working variants, including infection positive control **b.** no localized infection or other sign of infection in mice treated with nanosystem embedded EO.

4. Conclusions

The *in vivo* experimental infection on holoxenic mice, revealed the protective effect exhibited by the nanosystem embedded essential oil against the occurrence of localized infections in mice injected with *P. aeruginosa* viable culture. The *Eugenia carryophyllata* essential oil exhibited an early microbicidal effect on all tested *P. aeruginosa* and *S. aureus* stains, with significantly lower MIC values for *S. aureus* strains. The essential oil modulated the expression of soluble virulence factors, by increasing the production of lipase in both species, and of DN-ase, gelatinase, haemolysins and lecithinase, particulary in *P. aeruginosa* strains. The anti-apoptotic effect obtained on HeLa cells suggests a possible anti-tumoral effect of the essential oil oil suggest that they could be improved and stabilized by embedding it in a nanosystem that could act as a delivery system formulation.

5. References

[1] Kloos W.E., Schleifer, K.-H., Gotz, F., The Prokaryotes, A Handbook on the Biology of Bacteria: Ecophysiology, Isolation, Identi¢cation, Application 2nd ed., Vol. II, Springer-Verlag, **1992**

[2] Lowy F.D., Staphylococcus aureus infections, N Engl J Med ,339: 520-532, 1998

[3] Menichetti F., Current and emerging serious Gram-positive infections, *Clin Microbiol Infect*, 3, 22–28, **2005**

[4] Hutchison M. L., Govan, J. R., Pathogenicity of microbes associated with cystic fibrosis, *Microbes Infect.*, 1, 1005–1014, **1999**

[5] Chastre, J., Fagon, J. Y., Chastre, J., Fagon, J. Y., Ventilator-associated Pneumonia, *Am. J. Respir. Crit. Care Med.* 165, 867–903, **2002**

[6] Ortan A., Câmpeanu G., Dinu – Pîrvu C., Popescu L., Studies concerning the entrapment of Anethum graveolens essential oil in Liposomes, *Rom. Biotechnol. Lett.*, 14, 4411, **2009**

[7] Saviuc C., Grumezescu A.M., Chifiriuc C.M., Mihaiescu D.E., Hristu R., Stanciu G., Oprea E., Radulescu V., Lazar V., Hybrid nanosystem for stabilizing essential oils in biomedical applications, *Digest Journal of Nanomaterials and Biostructures*, in press

[8] Saviuc C., Grumezescu A.M., Oprea E., Radulescu V., Dascalu L., Chifiriuc M.C., Bucur M., Banu O., Lazar V., Antifungal activity of some vegetal extracts on *Candida* biofilms developed on inert substratum, *Biointerface Research in Applied Chemistry*, 1, 1, 15-23, **2011**

[9] Buteică A. S., Mihaiescu D. E., Grumezescu A. M., Vasile B. S., Popescu A., Mihaiescu O. M., Cristescu R., The anti-bacterial activity of magnetic nanofluid: Fe_3O_4 /oleic acid/cephalosporins core/shell/adsorptionshell proved on S. aureus and E. coli and possible applications as drug delivery systems, *Digest Journal of Nanomaterials and Biostructures*, 5, 4, 927, **2010**

[10] Saviuc C., Grumezescu A. M., Bleotu C., Banu O., Mihaiescu D., Chifiriuc M.C., Lazar V., Culture methods versus flow citometry for the comparative assessment of antifungal activity of *Eugenia Caryophyllata (Thunb., Myrtaceae)*, Al VII-lea Congres National De Citometrie, Bucuresti, 5-7 mai 2011

Acknowledgement: This research was financed by the European Funding Program *POSDRU 107/1.5/S/80765*